Literature DB >> 6131123

Intrinsic sympathomimetic activity of the partial agonist prenalterol in relation to beta adrenoceptor interaction in various tissues, in vitro.

H Mattsson, A Hedberg, E Carlsson.   

Abstract

The intrinsic sympathomimetic activity (ISA) of prenalterol was studied in isolated tissues from different species, including tissues containing predominantly beta-1 adrenoceptors (cardiac preparations from cat, rabbit, rat and guinea pig) and tissues characterized by beta-2 adrenoceptor predominance (cat skeletal muscle and rat uterus). The ISA of prenalterol, varying between 0 and 94% in the various tissues, was found to be positively correlated to the stimulatory potency (-log EC50) of isoproterenol and prenalterol. In the cardiac preparations from the rabbit there was an interindividual variation in the ISA of prenalterol, which was also positively correlated to the stimulatory potency of the beta agonists. The density of beta adrenoceptors in the tissues studied correlated neither to the variable ISA of prenalterol nor to the -log EC50 values of isoproterenol or prenalterol. The affinities of isoproterenol and prenalterol for the beta adrenoceptors were subject to less variation than were the stimulatory potencies of the agonists. The degree of separation between the concentration-effect curves for beta adrenoceptor occupancy and mechanical performance, expressed as the ratios Kd/EC50 for both agonists, were positively correlated to the corresponding ISA of prenalterol in various tissues. However, a considerably steeper relationship between occupancy/potency ratio and ISA was seen with prenalterol than with isoproterenol. The present data suggest that the level of ISA of the partial agonist, prenalterol, depends upon the efficiency of signal transmission from the activated receptor to the final end-organ response. The separation between the concentrations of the full agonist, isoproterenol, required for receptor occupancy and response serves as an index of the efficiency of coupling between the stimulus, elicited by activation of the receptor, and the response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131123

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

2.  Muscarinic receptor interaction with full and partial beta-adrenoceptor agonists in the rat colon strip.

Authors:  B Ek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

3.  The influence of molecular structure on the affinity and efficacy of some beta-adrenoceptor agonists.

Authors:  P Molenaar; G A McPherson; E Malta; C Raper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

4.  The in vitro pharmacology of xamoterol (ICI 118,587).

Authors:  E Malta; M A Mian; C Raper
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

5.  Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat.

Authors:  A Hedberg; H Mattsson; V Nerme; E Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

6.  The inhibitory GTP-binding protein (Gi) regulates the agonistic property of beta-adrenergic ligands in isolated rat adipocytes. Evidence for a priming effect of cyclic AMP.

Authors:  C Wesslau; U Smith
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

7.  The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.

Authors:  T Abrahamsson
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.